Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Alterity Therapeutics Limited - American Depositary Shares (NQ: ATHE )

3.940 +0.160 (+4.23%)
Streaming Delayed Price Updated: 3:59 PM EDT, Mar 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 19,956
Open 3.800
Bid (Size) 3.920 (2)
Ask (Size) 4.000 (1)
Prev. Close 3.780
Today's Range 3.800 - 4.010
52wk Range 1.001 - 5.870
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Alterity Therapeutics Raises A$40.0 million in Placement
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Wondering what's happening in today's after-hours session?
The US market regular session of Friday is over, let's have a look at the top gainers and losers in the after hours session today. 
Via Chartmill

Performance

YTD
+5.63%
+5.63%
1 Month
-9.22%
-9.22%
3 Month
+77.48%
+77.48%
6 Month
+212.70%
+212.70%
1 Year
+110.70%
+110.70%

More News

Read More
Nasdaq Moves Lower; Meta Platforms Posts Strong Sales
Via Benzinga
What's Going On With Alterity Therapeutics Shares Thursday?
Via Benzinga
Dow Jumps Over 100 Points; Tesla Earnings Miss Views
Via Benzinga
Topics Earnings Stocks
Exposures Financial US Equities
Alterity Therapeutics Stock Doubles Premarket On Positive MSA Trial Results: Retail Excitement Soars
Via Stocktwits
Alterity Therapeutics Announces Positive ATH434 Phase 2 Trial Results in Multiple System Atrophy Led By Robust Clinical Efficacy
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Why Meta Platforms Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Via Benzinga
Appendix 4C – Q2 FY25 Quarterly Cash Flow Report
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming Milestones
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Alterity Therapeutics Completes Last Patient Visit in ATH434-201 Phase 2 Clinical Trial in Early-Stage Multiple System Atrophy
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Alterity Therapeutics Appoints Abby Macnish Niven as Company Secretary
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Alterity Therapeutics Announces Presentation on Tracking the Progression of Multiple System Atrophy at International Symposium
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Alterity Therapeutics Announces New Publication Describing Novel Mechanism of Action for ATH434
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Appendix 4C – Q1 FY25 Quarterly Cash Flow Report
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Alterity Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on 17 October 2024
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Alterity Therapeutics Announces Presentation of New Data Describing Neuroprotection of ATH434 at Neuroscience Meeting
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Alterity Therapeutics Raises Profile with Multiple Data Presentations at the International Congress of Parkinson’s Disease and Movement Disorders®
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Alterity Therapeutics Appoints Abby Macnish Niven as Chief Financial Officer
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Alterity Therapeutics to Deliver Multiple Oral and Poster Presentations at the International Congress of Parkinson’s Disease and Movement Disorders®
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Appendix 4C – Q4 FY24 Quarterly Cash Flow Report
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Alterity Therapeutics to Present at MST Financial Webinar
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.